Newer anti-diabetic agents such as sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors are very useful in that they rarely cause common adverse effects of other oral hypoglycemic agents, such as weight gain and hypoglycemia. The gene discussed is SLC5A2; the disease is Hypoglycemia.